| Literature DB >> 36079735 |
Sergio Ruiz-Saavedra1,2, Aida Zapico2,3, Carmen González Del Rey4, Celestino Gonzalez3, Adolfo Suárez2,5, Ylenia Díaz6, Clara G de Los Reyes-Gavilán1,2, Sonia González2,3.
Abstract
Whereas the mechanisms underlying the association of toxic dietary xenobiotics and cancer risk are not well established, it is plausible that dietary pattern may affect the colon environment by enhancing or reducing exposure to mutagens. This work aimed to investigate the association between xenobiotics intake and different stages of intestinal mucosal damage and colorectal cancer (CRC) screening and examine whether these associations may be mediated by altered intestinal mutagenicity. This was a case control study with 37 control subjects, 49 patients diagnosed with intestinal polyps, and 7 diagnosed with CRC. Lifestyle, dietary, and clinical information was registered after colonoscopy. For xenobiotics intake estimation the European Prospective Investigation into Cancer (EPIC) and the Computerized Heterocyclic Amines Resource for Research in Epidemiology of Disease (CHARRED) databases were used. The mutagenicity of fecal supernatants was assayed by the Ames test and light microscopy was used for the presence of aberrant crypt formation. Among all the potential carcinogens studied, the polyp group showed higher intakes of ethanol and dibenzo (a) anthracene (DiB(a)A). Besides, intakes between 0.75 and 1.29 µg/d of total polycyclic aromatic hydrocarbons (PAHs) were related with a higher risk of belonging to the polyp group. On the contrary, an intake of wholegrain cereals greater than 50 g/d was associated with a reduction in the relative risk of belonging to the polyp group. Heterocyclic amines (HAs) such as 2-amino-1-methyl-6-phenylimidazo (4,5,b) pyridine (PhIP) were associated with an increased level of mutagenicity in polyps. This study is of great interest for the identification of possible therapeutic targets for the early prevention of colon cancer through diet.Entities:
Keywords: colorectal cancer; fecal mutagenicity; food processing; potential carcinogens; xenobiotics
Mesh:
Substances:
Year: 2022 PMID: 36079735 PMCID: PMC9458229 DOI: 10.3390/nu14173482
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 6.706
Figure 1Graphical information on the study design and sample size. The left column information indicates the variables studied and the right column text indicates the methodology or the raw material used to study those variables. Each box in the central part of the figure shows the number of volunteers belonging to the different diagnosis group, with available data for each of the determinations. CRC, colorectal cancer; DxBx, pathological analysis.
General description of the sample population according to diagnosis group.
| Control | Polyps | CRC | |
|---|---|---|---|
| Male gender | 17 (45.95) a | 30 (61.22) a | 7 (100.00) b |
| Age (years) | 60 (54–66) a | 63 (56–66) a | 63 (61–70) a |
| Energy intake (kcal/d) | 1974.87 (1492.99–2463.87) a | 1926.43 (1691.48–2675.80) a | 2070.43 (1915.76–2830.29) a |
| BMI (kg/m2) | 25.70 (23.67–28.94) a | 27.56 (25.14–31.22) b | 24.68 (24.21–29.32) a |
| CRC history (1st grade) | 9 (24.32) a | 11 (22.45) a | 1 (14.29) a |
| Physical activity (min/d) | 75.00 (37.50–75.00) a | 50.00 (37.50–75.00) a | 90.00 (75.00–90.00) b |
| Sleeping (hours/d) | 7.00 (6.00–7.25) a | 7.00 (6.00–8.00) a | 7.00 (6.00–8.00) a |
| Current smoker | 6 (16.22) a | 13 (26.53) a | 1 (14.29) a |
| Gastrointestinal functionality | |||
| Deposition/week | 8.50 (6.00–8.50) a | 7.00 (6.00–8.50) a | 8.50 (8.50–8.50) a |
| Liquid feces | 0 (0.00) a | 1 (2.04) a | - |
| Soft feces | 27 (72.97) a | 32 (65.31) a | 5 (71.43) a |
| Hard feces | 10 (27.03) a | 16 (32.65) a | 2 (28.57) a |
| Pathological analysis (DxBx) | |||
| HP | 4 (10.81) a | 7 (14.29) a | 0 (0.00) a |
| TA | 0 (0.00) a | 22 (44.90) b | - |
| TVA | 0 (0.00) a | 5 (10.20) b | - |
| SSA | 0 (0.00) a | 1 (2.04) a | - |
| HGD | 0 (0.00) a | 6 (12.24) b | - |
| AC | 0 (0.00) a | 1 (2.04) a | 7 (100.00) b |
| LSC | 24 (64.86) a | 3 (6.12) b | 0 (0.00) b |
| Not available | 9 (24.32) a | 4 (8.16) b | 0 (0.00) a |
Values are presented as median (IQR = interquartile range = Q1–Q3) for continuous variables or number (%) for categorical ones. Values in the same row showing different subscripts present a statistically significant difference (p ≤ 0.05) than control group. BMI, body mass index; CRC, colorectal cancer; DxBx, pathological analysis; HP, hyperplastic polyps; TA, tubular adenoma; TVA, tubulovillous adenoma; SSA, sessile serrated adenoma; HGD, high-grade dysplasia; AC, adenocarcinoma; LSC, less severe conditions.
Figure 2Analysis of the dietary and lifestyle significant risk factors for CRC according to GBD and clinical diagnosis group. The control group is used for comparison. BMI, body mass index; CRC, colorectal cancer; GBD, Global Burden of Diseases, Injuries, and Risk Factors Study; MET, metabolic equivalent of task. (*) p-value < 0.05.
Differences in the median intake of bioactive and carcinogenic compounds in the total sample and by diagnosis group.
| Variables | Total Sample | Diagnosis Group | ||
|---|---|---|---|---|
| Control | Polyps | CRC | ||
| Bioactive | ||||
| Total fiber (g/d) | 20.88 (14.77–25.15) | 21.89 (14.77–26.87) a | 20.41 (15.22–23.75) a | 22.33 (13.80–29.55) a |
| Insoluble fiber (g/d) | 12.50 (8.66–15.08) | 12.50 (8.66–16.57) a | 12.29 (9.25–14.64) a | 13.27 (8.04–17.70) a |
| Soluble fiber (g/d) | 2.40 (1.87–3.06) | 2.62 (1.86–3.17) a | 2.32 (1.88–2.85) a | 2.77 (1.91–3.03) a |
| Cellulose (g/d) | 5.01 (3.62–6.39) | 5.01 (3.50–6.40) a | 4.93 (3.64–6.24) a | 5.35 (2.97–8.02) a |
| Insoluble hemicellulose (g/d) | 3.88 (2.80–4.90) | 4.02 (2.86–5.38) a | 3.63 (2.68–4.51) a | 4.01 (2.69–5.48) a |
| Soluble hemicellulose (g/d) | 1.65 (1.15–2.27) | 1.77 (1.09–2.32) a | 1.57 (1.19–2.04) a | 1.90 (1.04–2.35) a |
| Insoluble pectin (g/d) | 1.34 (1.01–1.96) | 1.53 (1.11–2.02) a | 1.29 (0.94–1.81) a | 1.58 (1.20–2.06) a |
| Soluble pectin (g/d) | 0.66 (0.51–0.89) | 0.70 (0.55–0.92) a | 0.62 (0.45–0.88) a | 0.69 (0.58–1.29) a |
| Klason lignin (g/d) | 1.63 (1.22–2.26) | 1.63 (1.30–2.26) a | 1.69 (1.22–2.11) a | 1.42 (1.13–2.44) a |
| Total polyphenols (mg/d) | 1482.46 (963.00–1951.48) | 1509.00 (1074.04–1877.40) a | 1376.33 (904.37–1951.48) a | 1454.97 (1000.45–2051.10) a |
| Flavonoids (mg/d) | 128.09 (72.89–302.17) | 136.93 (78.28–251.34) a | 122.87 (53.65–331.58) a | 174.05 (80.98–498.80) a |
| Lignans (mg/d) | 46.95 (26.29–74.22) | 47.39 (28.61–85.26) a | 40.18 (22.28–60.34) a | 55.39 (30.43–92.01) a |
| Other polyphenols (mg/d) | 24.27 (15.19–42.26) | 27.32 (16.37–45.15) a | 19.93 (14.86–35.08) a | 29.48 (19.32–60.48) a |
| Phenolic acids (mg/d) | 496.08 (211.63–836.53) | 609.92 (222.81–958.37) a | 386.62 (188.52–781.00) a | 496.08 (262.91–1223.65) a |
| Stilbenes (mg/d) | 0.11 (0.04–0.76) | 0.09 (0.04–0.36) a | 0.16 (0.03–1.87) a | 0.11 (0.04–2.10) a |
|
| ||||
| Ethanol (g/d) | 2.18 (0.19–10.56) | 1.88 (0.28–8.80) a | 8.13 (1.76–22.93) b | 6.02 (0.00–24.46) a |
| Xenobiotics | ||||
| B(a)P (µg/d) | 0.06 (0.04–0.08) | 0.06 (0.05–0.08) a | 0.06 (0.04–0.08) a | 0.07 (0.03–0.08) a |
| DiB(a)A (µg/d) | 0.03 (0.01–0.10) | 0.03 (0.00–0.04) a | 0.05 (0.01–0.15) b | 0.03 (0.00–0.32) a |
| Total PAH (µg/d) | 1.09 (0.66–1.44) | 0.93 (0.58–1.44) a | 1.15 (0.75–1.43) a | 1.22 (1.07–1.46) a |
| PhlP (ng/d) | 82.56 (25.14–232.97) | 77.78 (24.45–182.10) a | 82.64 (23.79–329.91) a | 83.12 (36.77–222.53) a |
| DiMelQx (ng/d) | 6.67 (3.29–14.72) | 5.13 (3.00–13.83) a | 6.90 (3.47–16.83) a | 9.96 (4.53–18.22) a |
| MelQx (ng/d) | 23.50 (13.44–61.12) | 22.15 (13.44–61.12) a | 23.24 (13.42–56.27) a | 25.27 (16.64–69.07) a |
| MelQ (ng/d) | 0.81 (0.00–1.68) | 0.93 (0.34–1.82) a | 0.81 (0.00–1.30) a | 0.00 (0.00–2.16) a |
| IQ (ng/d) | 0.13 (0.00–0.27) | 0.13 (0.00–0.25) a | 0.13 (0.00–0.27) a | 0.00 (0.00–0.17) a |
| Total HAs (sum) (ng/d) | 119.54 (53.34–315.45) | 103.17 (46.23–269.12) a | 125.27 (53.95–381.99) a | 185.87 (83.32–245.86) a |
| Nitrates (mg/d) | 91.15 (55.92–140.60) | 95.09 (65.41–140.60) a | 69.44 (55.74–113.17) a | 97.39 (54.94–186.96) a |
| Nitrites (mg/d) | 2.39 (1.52–4.17) | 2.48 (1.74–4.34) a | 2.37 (1.31–4.17) a | 2.44 (1.73–2.62) a |
| NDMA (µg/d) | 0.16 (0.11–0.30) | 0.16 (0.10–0.28) a | 0.16 (0.11–0.30) a | 0.17 (0.13–0.35) a |
| NPIP (µg/d) | 0.07 (0.04–0.11) | 0.08 (0.05–0.11) a | 0.07 (0.03–0.11) a | 0.06 (0.04–0.08) a |
| NPYR (µg/d) | 0.11 (0.06–0.18) | 0.12 (0.08–0.17) a | 0.10 (0.05–0.18) a | 0.09 (0.07–0.12) a |
| Acrylamide (µg/d) | 14.70 (8.66–24.20) | 15.07 (8.66–25.11) a | 14.70 (8.06–21.42) a | 14.15 (13.29–36.22) a |
Values are presented as median (IQR = interquartile range = Q1–Q3). Values in the same row showing different subscripts display a statistically significant difference (p ≤ 0.05) from the control group. AαC (amino-alpha-carboline) and Comb. (combined nitroso compounds) are removed from the analysis due to extremely low frequency of consumption. B(a)P, benzo (a) pyrene; DiB(a)A, dibenzo (a) anthracene; Total PAHs, total polycyclic aromatic hydrocarbons; PhIP, 2-amino-1-methyl-6-phenylimidazo (4,5,b) pyridine; DiMeIQx, 2-amino-3,4,8 trimethylimidazo (4,5,f) quinoxaline; MeIQx, 2-amino-3,8 dimethylimidazo (4,5,f) quinoxaline; MeIQ, 2-amino-3,4 dimethylimidazo (4,5,f) quinoline; IQ, 2-amino-3-methylimidazo (4,5,f) quinoline; Total HA, total heterocyclic amines. NDMA, N-nitrosodimethylamine; NPIP, N-nitrosopiperidine; NPYR, N-nitrosopyrrolidine.
GBD risk-related factors, bioactive and carcinogen tertiles as predictors of polyp risk.
| N (%) | Mean ± SD | OR (95% CI) | ||
|---|---|---|---|---|
| GBD factors | ||||
| BMI | ||||
| 5 kg/m2 | 93 (100) | 27.24 ± 4.06 | 1.705 (0.975–2.980) | 0.061 |
| Alcoholic beverages (g/d) | ||||
| ≤48.00 | 32 (37) | 11.10 ± 14.11 | – | – |
| >48.00 | 54 (63) | 442.81 ± 559.93 | 2.539 (0.997–6.467) | 0.051 |
| Whole grains (g/d) | ||||
| ≤50.00 | 78 (91) | 5.47 ± 11.66 | – | – |
| >50.00 | 8 (9) | 130.69 ± 107.33 | 0.168 (0.029–0.966) | 0.046 * |
|
| ||||
| Soluble pectin (g/d) | ||||
| ≤0.57 | 32 (37) | 0.43 ± 0.09 | – | – |
| 0.57–0.85 | 29 (34) | 0.71 ± 0.08 | 0.357 (0.117–1.089) | 0.070 |
| ≥0.85 | 25 (29) | 1.33 ± 0.60 | 0.408 (0.125–1.327) | 0.136 |
| Flavonoids (mg/d) | ||||
| ≤82.18 | 28 (33) | 44.96 ± 22.29 | – | – |
| 82.18–251.34 | 30 (35) | 152.20 ± 55.08 | 0.343 (0.112–1.052) | 0.061 |
| ≥251.34 | 28 (33) | 525.49 ± 323.63 | 1.099 (0.347–3.482) | 0.872 |
| Other polyphenols (mg/d) | ||||
| ≤16.45 | 30 (35) | 11.26 ± 4.56 | – | – |
| 16.45–32.15 | 28 (33) | 23.91 ± 5.00 | 0.761 (0.249–2.324) | 0.631 |
| ≥32.15 | 28 (33) | 74.05 ± 52.77 | 0.358 (0.116–1.107) | 0.074 |
|
| ||||
| Ethanol (g/d) | ||||
| ≤1.70 | 29 (34) | 0.39 ± 0.56 | – | – |
| 1.70–11.62 | 28 (33) | 5.33 ± 3.24 | 1.720 (0.575–5.148) | 0.332 |
| ≥11.62 | 29 (34) | 35.12 ± 25.93 | 3.542 (1.117–11.234) | 0.032 * |
| DiB(a)A (µg/d) | ||||
| ≤0.01 | 29 (34) | 0.00 ± 0.00 | – | – |
| 0.01–0.07 | 28 (33) | 0.04 ± 0.01 | 0.587 (0.191–1.803) | 0.352 |
| ≥0.07 | 29 (34) | 0.34 ± 0.33 | 3.100 (0.950–10.118) | 0.061 |
| Total PAH (µg/d) | ||||
| ≤0.75 | 30 (35) | 0.57 ± 0.14 | – | – |
| 0.75–1.29 | 27 (31) | 1.07 ± 0.14 | 3.753 (1.154–12.204) | 0.028 * |
| ≥1.29 | 29 (34) | 1.77 ± 0.37 | 1.530 (0.510–4.595) | 0.448 |
| Nitrates (mg/d) | ||||
| ≤63.75 | 29 (34) | 44.77 ± 13.95 | – | – |
| 63.75–106.65 | 28 (33) | 85.25 ± 12.54 | 0.561 (0.182–1.729) | 0.314 |
| ≥106.65 | 29 (34) | 206.06 ± 102.67 | 0.371 (0.121–1.133) | 0.082 |
| Nitrites (mg/d) | ||||
| ≤1.69 | 30 (35) | 1.16 ± 0.38 | – | – |
| 1.69–3.34 | 26 (30) | 2.45 ± 0.45 | 0.297 (0.094–0.944) | 0.040 * |
| ≥3.34 | 30 (35) | 8.38 ± 13.07 | 0.515 (0.168–1.584) | 0.247 |
The variables considered in this analysis were age, sex, risk of GBD-related factors (alcoholic beverages: 12, 24, 36, 48, 60, and 72 g/d; whole grains: 50, 100, and 150 g/d; milk: 60, 120, 180, and 240 g/d; red meat: 50, 100, 150, and 200 g/d; processed meat: 25, 50, 75, and 100 g/d; fiber: 10, 20, and 30 g/d; calcium: 300, 600, 900, and 1200 mg/d; physical activity: 2400, 3000, 3600, and 4200 METs/d; BMI: 5 kg/m2) and tertiles of consumption of all bioactives and carcinogens. Only variables showing significant (*) p-value < 0.05 or proximal (p-value < 0.10) results in at least one category are shown. For each variable considered, the lowest tertile is considered as the reference group. Values are adjusted for BMI and age. BMI, body mass index; CI, confidence interval; CRC, colorectal cancer; DiB(a)A, dibenzo (a) anthracene; GBD, Global Burden of Diseases, Injuries, and Risk Factors Study; MET; metabolic equivalent of task; OR, odds ratio.
Figure 3Dot plots comparing the mutagenicity of volunteers’ fecal samples according to (a) the clinical endoscopic diagnosis group and (b) the ACF occurrence. The fecal mutagenicity for each volunteer is represented by colored circles. Wide horizontal lines indicate the median for each condition and error bars represent the interquartile range or the range for the CRC group. (*) Significant differences between groups (p ≤ 0.05). (c) ACF occurrence and type (hyperplastic, dysplastic, or without cellular morphological alterations) in the sample for each clinical endoscopic diagnosis group (control, polyps, and CRC). Each bar represents the number of cases detected for each ACF category in each diagnosis group. ACF, aberrant crypt foci; CRC, colorectal cancer.
Figure 4Photographs of histological sections showing ACF (H&E stain). Non-dysplasic distorted architecture (cells without morphological alterations) ((A,B), ×100). Hyperplastic with “serrated” lumen, “sawtooth” appearance ((C,D), ×100). Low-grade dysplasia with enlarged crypts, nuclear stratification, mucin depletion, elongated and hyperchromatic nuclei with loss of nuclear polarity and associated lymphocytic infiltrate ((E), ×200; (F), ×100). ACF, aberrant crypt foci; H&E, hematoxylin and eosin stain.
Figure 5Heatmap defined by Spearman correlations between fecal mutagenicity and (a) food groups, (b) bioactive compounds, and (c) xenobiotics. Blue and red colors represent negative and positive associations, respectively. The color intensity is proportional to the degree of association between fecal mutagenicity and the factors considered. (*) p ≤ 0.05.
Figure 6Major dietary sources of (a) polycyclic aromatic hydrocarbons; (b) heterocyclic amines; (c) nitrates, nitrites, and nitroso compounds; and (d) acrylamide in the sample. Only the most frequently consumed xenobiotics were considered. For each compound, food items accounting for at least 80% of total intake were included. B(a)P, benzo (a) pyrene; DiB(a)A, dibenzo (a) anthracene; DiMeIQx, 2-amino-3,4,8 trimethylimidazo (4,5,f) quinoxaline; MeIQx, 2-amino-3,8 dimethylimidazo (4,5,f) quinoxaline; NDMA, N-nitrosodimethylamine; NPIP, N-nitrosopiperidine; NPYR, N-nitrosopyrrolidine; PhIP, 2-amino-1-methyl-6-phenylimidazo (4,5,b) pyridine; Total HAs, total heterocyclic amines; Total PAHs, total polycyclic aromatic hydrocarbons.